... the Department of Energy,s Oak Ridge National Laboratory and ... developing nerve cells may hold a key to predicting ... disease. , St. Jude scientists have linked movement and ... and retinas of young mice to certain diseases. Now, ...
... discovered that cane toads are far more susceptible to being ... research published in the British Ecological Society,s journal ... toad,s armour that could help control the spread of this ... and his colleagues Georgia Ward-Fear, Matt Greenlees and Greg Brown ...
... new, environmentally friendly coating that protects metals against ... team of researchers from Sheffield Hallam University. At ... today, (Monday 30 March), Jeanette Gittens and colleagues ... bacterium into a sol-gel coating which then protected ...
Other Biology News:ORNL, St. Jude track neurons to predict and prevent disease 2Aussie meat ants may be invasive cane toad's Achilles' heel 2(Date:12/14/2009)... -- Decision Resources, one of the world,s leading ... issues, finds that, owing to the launches of ... will increase more than sevenfold from $790 million ... the United States, France, Germany, Italy, Spain, the ... report entitled Atrial Fibrillation finds that ...
(Date:12/11/2009)... Dendreon Corporation (Nasdaq: DNDN ) announced today ... offering have exercised in full their option to ... at the public offering price of $24.75 per ... the size of the offering to an aggregate ... expects to receive net proceeds from the offering ...
(Date:12/11/2009)... Ambit Biosciences Corporation announced today the enrollment and dosing ... Center of the first patient in the ACE ( ... fficacy) Phase 2 pivotal trial in patients with relapsed ... a novel, orally available, potent and highly selective small ... kinase-3 (FLT3) inhibitor. The ACE study is designed ...
(Date:12/11/2009)... Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" or ... Alan Warrander to the role of Senior Vice ... Warrander will be responsible for the execution of ... Brad Thompson, President and CEO of Oncolytics. "Having ... Phase 3 trial examining REOLYSIN in combination with ...
Breaking Biology Technology:The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3